ATE145337T1 - Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen - Google Patents

Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen

Info

Publication number
ATE145337T1
ATE145337T1 AT89908564T AT89908564T ATE145337T1 AT E145337 T1 ATE145337 T1 AT E145337T1 AT 89908564 T AT89908564 T AT 89908564T AT 89908564 T AT89908564 T AT 89908564T AT E145337 T1 ATE145337 T1 AT E145337T1
Authority
AT
Austria
Prior art keywords
compounds
bio
methods
particles
substances
Prior art date
Application number
AT89908564T
Other languages
English (en)
Inventor
Paul Karl Horan
Sue Ellen Slezak
Brian David Gray
Georges L Dunn
Original Assignee
Phanos Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phanos Tech Inc filed Critical Phanos Tech Inc
Application granted granted Critical
Publication of ATE145337T1 publication Critical patent/ATE145337T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0085—Mossbauer effect therapy based on mossbauer effect of a material, i.e. re-emission of gamma rays after absorption of gamma rays by the material; selective radiation therapy, i.e. involving re-emission of ionizing radiation upon exposure to a first ionizing radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1896—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes not provided for elsewhere, e.g. cells, viruses, ghosts, red blood cells, virus capsides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1258—Pills, tablets, lozenges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
AT89908564T 1988-05-02 1989-01-10 Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen ATE145337T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18919288A 1988-05-02 1988-05-02

Publications (1)

Publication Number Publication Date
ATE145337T1 true ATE145337T1 (de) 1996-12-15

Family

ID=22696320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89908564T ATE145337T1 (de) 1988-05-02 1989-01-10 Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen

Country Status (9)

Country Link
US (2) US5667764A (de)
EP (1) EP0430968B1 (de)
JP (1) JP3038339B2 (de)
AT (1) ATE145337T1 (de)
AU (1) AU641361B2 (de)
CA (1) CA1336272C (de)
DE (1) DE68927479T2 (de)
IL (1) IL90030A (de)
WO (1) WO1989010758A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038339B2 (ja) * 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US5562894A (en) * 1991-08-09 1996-10-08 Regents Of The University Of California Amino-acyl-type and catecholamine-type contrast agents for MRI
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2124329C (en) * 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
US7166423B1 (en) 1992-10-21 2007-01-23 Miltenyi Biotec Gmbh Direct selection of cells by secretion product
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
CN100998565A (zh) * 1993-07-19 2007-07-18 血管技术药物公司 抗血管生长组合物及使用方法
DE69434598T3 (de) * 1993-07-29 2010-07-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose
US5480901A (en) * 1994-10-07 1996-01-02 Zynaxis, Inc. Method for reducing unwanted cellular adhesions
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US7846202B2 (en) * 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US7896914B2 (en) 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7867275B2 (en) 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
DE19539409C2 (de) * 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
US5804389A (en) * 1995-12-29 1998-09-08 Phanos Technologies, Inc. Method for detecting abnormal epithelial cell shedding
US6204002B1 (en) * 1996-10-22 2001-03-20 Daikin Industries, Ltd. Gangliosides having fluorescent-tagged ceramide moieties
US6117099A (en) 1996-10-23 2000-09-12 In-Line Diagnostics Corporation System and method for noninvasive hemodynamic measurements in hemodialysis shunts
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
GB9705521D0 (en) * 1997-03-18 1997-05-07 Univ Sheffield The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue
AU7563798A (en) * 1997-04-30 1998-11-24 Emory University Methods and compositions for administering dna to mucosal surfaces
US8974363B2 (en) * 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US20090117199A1 (en) * 1998-08-06 2009-05-07 Scott Timothy C Method of treatment of cancer
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU1932900A (en) 1998-12-04 2000-06-26 Medivas, Llc Methods for detection of vulnerable plaques using a detectable lipid-avid agent
US20050171594A1 (en) * 1998-12-31 2005-08-04 Angiotech International Ag Stent grafts with bioactive coatings
US20020065546A1 (en) * 1998-12-31 2002-05-30 Machan Lindsay S. Stent grafts with bioactive coatings
US6695830B2 (en) * 1999-01-15 2004-02-24 Scimed Life Systems, Inc. Method for delivering medication into an arterial wall for prevention of restenosis
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US6290673B1 (en) 1999-05-20 2001-09-18 Conor Medsystems, Inc. Expandable medical device delivery system and method
CA2273609A1 (en) * 1999-06-04 2000-12-04 Resolution Pharmaceuticals Inc. Radiopharmaceuticals and methods for imaging
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
WO2001066153A1 (en) 2000-03-03 2001-09-13 Phanos Technologies, Inc. Fluorescent membrane intercalating probes and methods for their use
IT1318401B1 (it) * 2000-03-17 2003-08-25 Indena Spa Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono.
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
DE60124285T3 (de) 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
PT1328213E (pt) 2000-10-16 2005-10-31 Conor Medsystems Inc Dispositivo medico expansivel para a administracao de um agente benefico
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US6964680B2 (en) 2001-02-05 2005-11-15 Conor Medsystems, Inc. Expandable medical device with tapered hinge
WO2002080885A1 (en) * 2001-04-03 2002-10-17 University Of Florida Detoxification and decontamination using nanotechnology therapy
US6977171B1 (en) 2001-04-03 2005-12-20 University Of Florida Detoxification and decontamination using nanotechnology therapy
US9157875B2 (en) * 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US20030105300A1 (en) * 2001-10-17 2003-06-05 Mallinckrodt Inc. Tumor targeted photodiagnostic-phototherapeutic agents
US6761878B2 (en) * 2001-10-17 2004-07-13 Mallinckrodt, Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents
ES2326040T3 (es) 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
US6723851B2 (en) 2001-10-31 2004-04-20 Quest Diagnostics Investment Incorporated Chemiluminescent compounds and use thereof
CA2490692A1 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
DK1521603T3 (da) 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
WO2004006963A1 (en) * 2002-07-12 2004-01-22 Beth Israel Deaconess Medical Center Conjugated infrared fluorescent substances for detection of cell death
GB0217556D0 (en) * 2002-07-30 2002-09-11 Amersham Biosciences Uk Ltd Site-specific labelling of proteins using cyanine dye reporters
JP2006505364A (ja) * 2002-11-08 2006-02-16 コナー　メドシステムズ，　インコーポレイテッド 血管新生因子の局所供給を用いる、慢性全梗塞を処置するための拡張可能な医療装置および方法
EP1581270A2 (de) * 2002-12-30 2005-10-05 Angiotech International Ag Seide enthaltende stents
EP2289571B1 (de) 2003-03-28 2016-08-03 Innovational Holdings, LLC Implantierbare medizinische vorrichtung mit kontinuerlichem gradienten einer therapeutischen substanz
US7169179B2 (en) 2003-06-05 2007-01-30 Conor Medsystems, Inc. Drug delivery device and method for bi-directional drug delivery
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US20050070602A1 (en) * 2003-09-30 2005-03-31 Jen-Wei Chiao Method of modulating immune response by administration of immuno-activation agent
AU2004289362A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Intravascular devices and fibrosis-inducing agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
JP5116480B2 (ja) 2004-11-22 2013-01-09 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
AU2005234696B2 (en) 2005-11-18 2012-02-16 Phanos Technologies, Inc. Fluorescent membrane intercalating probes and methods for their use
CN101679849B (zh) * 2006-09-06 2014-01-01 科德生物工程有限公司 荧光细胞标记物
EP2125058B1 (de) * 2007-02-07 2014-12-03 Cook Medical Technologies LLC Medizingerätbeschichtungen zur freisetzung eines therapeutischen wirkstoffs mit mehreren raten
US9724404B2 (en) 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
JP6444417B2 (ja) 2013-09-18 2018-12-26 オーラ バイオサイエンシーズ， インコーポレイテッド 腫瘍を診断および処置するためのウイルス様粒子結合体
US20180035486A1 (en) * 2015-02-20 2018-02-01 Telefonaktiebolaget Lm Ericsson (Publ) Control of Radio Connections in a Cellular Network
US10099961B2 (en) 2015-08-12 2018-10-16 United States Gypsum Company Fluorescent building product and related detection method
KR20180095511A (ko) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
WO2017173288A1 (en) 2016-04-01 2017-10-05 University Of Cincinnati Iodinated phenolic lipids and methods and cosolvent systems iodinaiton of phenolic lipids
US10859505B2 (en) * 2018-01-26 2020-12-08 Gemological Institute Of America, Inc. (Gia) Fluorescence box for gemological applications

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US925445A (en) * 1907-10-25 1909-06-22 Alfred James Bartlett Boomerang.
US925429A (en) * 1908-03-13 1909-06-15 Chadeloid Chemical Co Finish-remover and process of making the same.
US2647054A (en) * 1951-02-21 1953-07-28 Du Pont Photographic emulsions containing sensitizing dyes
GB723316A (en) * 1951-06-11 1955-02-09 Frederick Charles Bersworth Substituted alkylene polyamine acetic acid compounds
FR1477402A (fr) * 1959-06-30 1967-04-21 Commercial Solvents Corp Amines et leur procédé de préparation
US3228904A (en) * 1962-05-03 1966-01-11 Goodrich Co B F Stabilization of synthetic polymers
US3352791A (en) * 1965-01-22 1967-11-14 American Cyanamid Co Generation of light by the reaction of peroxide with heterocyclic derivatives
DE1251764B (de) * 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
JPS565981B1 (de) * 1969-03-07 1981-02-07
JPS4931895B1 (de) * 1969-05-17 1974-08-26
US3673410A (en) * 1969-06-25 1972-06-27 John H Waite Method of examination of cell samples using a radioactively tagged dye
BE754191R (fr) * 1969-07-30 1971-02-01 American Cyanamid Co Procede de preparation d'isocyanates
US3916069A (en) * 1973-04-02 1975-10-28 Minnesota Mining & Mfg Reduced styryl/cyanine dye
US4110116A (en) * 1973-06-18 1978-08-29 Minnesota Mining And Manufacturing Company Fogged direct positive silver halide emulsion containing a cyanine dye having at least one benzoxazole or benzothiazole nucleus substituted with halogen atoms
US4074046A (en) * 1974-01-21 1978-02-14 American Cyanamid Company Process for azoles (ring closure of nitro compounds)
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4343782A (en) * 1978-04-20 1982-08-10 Shapiro Howard M Cytological assay procedure
US4232000A (en) * 1978-06-28 1980-11-04 The Procter & Gamble Company Radioactive scanning agents with stabilizer
US4232121A (en) * 1978-09-25 1980-11-04 Eastman Kodak Company Process for selecting methine dyes which inhibit cell growth
DE2962152D1 (en) * 1978-10-18 1982-03-25 Ciba Geigy Ag Substituted 1,11-diamino undecanes, processes for their preparation and their use
US4424201A (en) * 1978-11-28 1984-01-03 Rockefeller University Employment of a mereyanine dye for the detection of malignant leukocytic cells
US4352751A (en) * 1979-09-10 1982-10-05 Analytical Radiation Corporation Species-linked diamine triacetic acids and their chelates
US4400370A (en) * 1980-03-12 1983-08-23 Lawrence Kass Metachromatic dye sorption means for differential determination of leukocytes
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
EP0047470B1 (de) * 1980-09-02 1985-04-24 Fuji Photo Film Co., Ltd. Verfahren zur immunochemischen Bestimmung
DE3105778A1 (de) * 1981-02-17 1982-09-02 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von trimethinfarbstoffen
US4500509A (en) * 1981-03-11 1985-02-19 Lawrence Kass Metachromatic dye sorption and fluorescent light emmisive means for differential determination of developmental stages of neutrophilic granulocytic cells and other leukocytes
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4471113A (en) * 1982-02-03 1984-09-11 The United States Of America As Represented By The Department Of Energy Prodrugs based on phospholipid-nucleoside conjugates
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4649151A (en) * 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
DE3238353A1 (de) * 1982-10-15 1984-04-19 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur simultanen quantitativen bestimmung der blutzellen und reagenz hierfuer
US4555396A (en) * 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
US4582700A (en) * 1983-09-01 1986-04-15 Mallinckrodt, Inc. Products and processes
US4670545A (en) * 1984-05-11 1987-06-02 University Patents, Inc. Chelating agents for technetium-99M
US4714606A (en) * 1984-05-15 1987-12-22 Cytocolor Incorporated Method of staining and identifying cells and compositions thereof
US4748129A (en) * 1984-08-28 1988-05-31 Snytex (U.S.A.) Inc. Assay method employing fluorescent cell incorporative dye
US4689292A (en) * 1984-11-11 1987-08-25 Konishiroku Photo Industry Co., Ltd. Silver halide photographic radiography light-sensitive material
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4815447A (en) * 1985-03-19 1989-03-28 Mills Randell L Mossbauer cancer therapy
DE3509822A1 (de) * 1985-03-19 1986-09-25 Bayer Ag, 5090 Leverkusen Aminobernsteinsaeurederivate und ihre verwendung als emulgatoren fuer polymerdispersionen
FR2601000B1 (fr) * 1986-07-03 1988-10-21 Centre Nat Rech Scient Procede de radio-iodation de gangliosides par voie enzymatique
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
US4783401A (en) * 1986-10-31 1988-11-08 Smithkline Beckman Corporation Viable cell labelling
US4762701A (en) * 1986-10-31 1988-08-09 Smithkline Beckman Corporation In vivo cellular tracking
US4859584A (en) * 1986-10-31 1989-08-22 Smithkline Beckman Corporation Cell growth rate determination by measurement of changes in cyanine dye levels in plasma membranes
US4775625A (en) * 1986-11-21 1988-10-04 The Medical College Of Wisconsin, Inc. Inactivating enveloped viruses with a merocyanine dye
FR2637895B1 (fr) * 1988-10-14 1992-11-06 Guerbet Sa Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands
US4906749A (en) * 1987-06-30 1990-03-06 Viomedics Inc. Cyclic anhydride derivatives of chromophors
NO884566L (no) * 1987-10-15 1989-04-17 Univ Moskovsk Anvendelse av fluorderivater og kontrastpreparat for diagnostisering av ondartede neoplasmer.
WO1989006654A1 (en) * 1988-01-19 1989-07-27 Board Of Regents, The University Of Texas System Glycosides, liposomal compositions thereof, and methods for their use
ES2058492T3 (es) * 1988-02-03 1994-11-01 Hybritech Inc Mejoras en o relativas a haptenos modificados utiles como agentes terapeuticos y de formacion de imagenes.
JP3038339B2 (ja) * 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US4906750A (en) * 1988-06-08 1990-03-06 Eastman Kodak Company Sulfoalkyl benzoxazoleinylidene butenylidene thiobarbituric acid derivatives
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
IL90730A0 (en) * 1988-06-24 1990-01-18 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
IL91414A0 (en) * 1988-08-31 1990-04-29 Zynaxis Technologies Inc Reagents and methods for the determination of analytes
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) * 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5149794A (en) * 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
FR2669633B1 (fr) * 1990-11-23 1993-01-22 Adir Nouveaux derives de la benzoselenazolinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
EP0430968B1 (de) 1996-11-20
JP3038339B2 (ja) 2000-05-08
JPH04502755A (ja) 1992-05-21
EP0430968A4 (en) 1993-10-20
IL90030A0 (en) 1989-12-15
IL90030A (en) 1995-12-08
AU641361B2 (en) 1993-09-23
WO1989010758A1 (en) 1989-11-16
US5665328A (en) 1997-09-09
DE68927479T2 (de) 1997-04-03
US5667764A (en) 1997-09-16
EP0430968A1 (de) 1991-06-12
CA1336272C (en) 1995-07-11
DE68927479D1 (de) 1997-01-02
AU3968589A (en) 1989-11-29

Similar Documents

Publication Publication Date Title
ATE145337T1 (de) Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
CA2124329A1 (en) Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
AP9901434A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
IL107109A0 (en) Compounds for modifying drug resistance and pharmaceutical compositions containing the same
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
FR2435471A1 (fr) Derives de dihydropyridine, procedes d'obtention et compositions pharmaceutiques en contenant
ES8205231A1 (es) Procedimiento para preparar complejos de platino (iv)-diami-na
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE68920798D1 (de) Substituierte Dihydroisochinolinone und verwandte Verbindungen als Verstärker der letalen Effekte von Bestrahlung und bestimmten Chemotherapeutika; ausgewählte Verbindungen, Analoga und Verfahren.
RU94036761A (ru) Производные галантамина и фармацевтическая композиция
ATE188873T1 (de) Tris-platin-komplexe
HU904201D0 (en) Process for producing peptides with haemoregulating effect and pharmaceutical preparatives containing these compounds
SE8901342L (sv) Biologiska material, foerfaranden foer framstaellning av biologiska material samt foer anvaendning av saadana material i terapi
FR2446829A1 (fr) Derives de polymethylene disubstitues en alpha, omega, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2434820A1 (fr) Complexes d'adn et d'esters de derives de la daunorubicine, leur preparation et les compositions pharmaceutiques qui les contiennent
ATE80802T1 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
FR2536075B1 (fr) Nouveaux derives de la nitrosouree, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE69814691T2 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
PT87704A (pt) Process for preparing pharmaceutical compositions for transdermal delivery containing a 1,4-dihydropyride derivative
KR20060095566A (ko) 방사선치료적 화학독성 제제로서 금속 트리카르보닐복합체의 용도
Zamora et al. Increased binding to sigma sites of N-[1′(2-piperidinyl) ethyl)-4-[I-125]-iodobenzamide (I-125-PAB) with onset of tumor cell proliferation
DK0658117T3 (da) Behandling af tumorer med neurotrofe faktorer og celleproliferationsinhibitorer
ES8300780A1 (es) Procedimiento para preparar oxido de bis(cloroetil-butilestano)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time